Bayesian Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bayesian Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-36,000	Closed	-$585K	–	643
2024 Q2	$585K	Buy	+36,000	New	+$581K	0.07%	329
2023 Q3	–	Sell	-11,837	Closed	-$283K	–	666
2023 Q2	$283K	Buy	11,837 +337	+3%	+$7.49K	0.03%	556
2023 Q1	$216K	Buy	+11,500	New	+$219K	0.03%	590
2022 Q3	–	Sell	-41,696	Closed	-$587K	–	664
2022 Q2	$587K	Buy	+41,696	New	+$778K	0.11%	285
2020 Q1	–	Sell	-5,900	Closed	-$252K	–	755
2019 Q4	$252K	Buy	+5,900	New	+$257K	0.04%	475
2017 Q4	–	Sell	-25,584	Closed	-$964K	–	528
2017 Q3	$964K	Buy	+25,584	New	+$832K	0.23%	137
2017 Q1	–	Sell	-14,800	Closed	-$427K	–	384
2016 Q4	$427K	Buy	+14,800	New	+$392K	0.11%	340

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Bayesian Capital Management's ACAD Position: Q3 2024 in Review

Bayesian Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 36,000 shares — an estimated $585K sold.

Bayesian Capital Management first reported a position in ACAD in Q4 2016 and held it in 7 quarters. The position peaked at $964K in Q3 2017. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

Bayesian Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Bayesian Capital Management sold 36,000 Acadia Pharmaceuticals shares in Q3 2024, an estimated $585K.
Bayesian Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2016 and held it in 7 quarters.
Bayesian Capital Management's Acadia Pharmaceuticals position peaked at $964K in Q3 2017.
256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.